Payment overview · 2025
General Payments
$1,889.68
49 reported records · 18 companies
Healthcare provider profile · identity verified
Robert F Manges, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · FORT WAYNE, IN · NPI 1508835174
Verified facts
What the public records show
CMS Open Payments records show Robert F Manges, MD received $1,889.68 in general payments during 2025 across 49 reported records.
Merck Sharp & Dohme LLC accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ayvakit, Imbruvica, Scemblix, Xpovio.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Venclexta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Tagrisso by this doctor in 2024.
Blueprint Medicines Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AYVAKIT as an associated drug or biological on 4288 records involving 3006 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ayvakit by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Sprycel by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AYVAKIT as an associated drug or biological on 4791 records involving 3585 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ayvakit by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Alecensa as an associated drug or biological on 194 records involving 149 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Alecensa by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Venclexta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Xarelto by this doctor in 2024.
Karyopharm Therapeutics Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XPOVIO as an associated drug or biological on 4911 records involving 2787 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xpovio by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SCEMBLIX as an associated drug or biological on 10426 records involving 5114 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Scemblix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $238.27 | 12.6% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $229.79 | 12.2% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $222.94 | 11.8% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $215.80 | 11.4% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $165.80 | 8.8% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $145.84 | 7.7% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $140.36 | 7.4% | 3 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $121.60 | 6.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $105.27 | 5.6% | 4 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $79.35 | 4.2% | 4 | 2025 |
| Galvanize Therapeutics, Inc | Unresolved — no canonical attribution shown | $36.86 | 1.9% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $34.34 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.97 | 1.7% | 2 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $29.92 | 1.6% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $28.96 | 1.5% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $28.58 | 1.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $18.66 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.37 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,889.68 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $238.27 | 11 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $222.94 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $222.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $215.80 | 7 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $148.01 | 2 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $139.47 | 2 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $121.60 | 1 | 2025 |
Source payment records
|
|||||
| CABLIVI Normalized: cablivi |
Biological | GENZYME CORPORATION | $118.72 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $117.76 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $105.27 | 4 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Biological | AstraZeneca Pharmaceuticals LP | $104.73 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $79.35 | 4 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological, Drug | Blueprint Medicines Corporation, GENZYME CORPORATION | $57.04 | 2 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $56.27 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $40.35 | 3 | 2025 |
Source payment records
|
|||||
| ALIYA SYSTEM Normalized: aliya system |
Device | Galvanize Therapeutics, Inc | $36.86 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $34.34 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $8.19 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AYVAKIT ayvakit |
2025 | Ayvakit | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SCEMBLIX scemblix |
2025 | Scemblix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XPOVIO xpovio |
2025 | Xpovio | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
99 | 12 |
| Blueprint Medicines Corporation Exact reporting entity; no affiliate inference |
2025 | AYVAKIT open payments reported associated product |
CMS Open Payments — General Payments 4288 supporting records · 3006 recipient NPIs · example record 1235804861 |
Ayvakit · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 64 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | AYVAKIT open payments reported associated product |
CMS Open Payments — General Payments 4791 supporting records · 3585 recipient NPIs · example record 1233194960 |
Ayvakit · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Alecensa open payments reported associated product |
CMS Open Payments — General Payments 194 supporting records · 149 recipient NPIs · example record 1211488956 |
Alecensa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
107 | 32 |
| Karyopharm Therapeutics Inc. Exact reporting entity; no affiliate inference |
2025 | XPOVIO open payments reported associated product |
CMS Open Payments — General Payments 4911 supporting records · 2787 recipient NPIs · example record 1246641449 |
Xpovio · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | SCEMBLIX open payments reported associated product |
CMS Open Payments — General Payments 10426 supporting records · 5114 recipient NPIs · example record 1200004731 |
Scemblix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Warfarin Sodium | Warfarin Sodium | 6753 | 1913 |
| Jantoven | Warfarin Sodium | 522 | 163 |
| Enoxaparin Sodium | Enoxaparin Sodium | 277 | 160 |
| Eliquis | Apixaban | 183 | 64 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 131 | 92 |
| Ondansetron Hcl | Ondansetron Hcl | 130 | 90 |
| Acyclovir | Acyclovir | 126 | 36 |
| Xarelto | Rivaroxaban | 107 | 32 |
| Dexamethasone | Dexamethasone | 101 | 65 |
| Tagrisso | Osimertinib Mesylate | 99 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 77 | 47 |
| Imbruvica | Ibrutinib | 73 | suppressed |
| Venclexta | Venetoclax | 73 | 15 |
| Prednisone | Prednisone | 55 | 28 |
| Hydroxyurea | Hydroxyurea | 51 | 11 |
| Brukinsa | Zanubrutinib | 46 | suppressed |
| Bosulif | Bosutinib | 45 | suppressed |
| Calquence | Acalabrutinib Maleate | 45 | suppressed |
| Lenalidomide | Lenalidomide | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 14 |
| Pomalyst | Pomalidomide | 32 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | 11 |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Ayvakit | Avapritinib | 24 | suppressed |
| Doptelet | Avatrombopag Maleate | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | 11 |
| Inqovi | Decitabine/Cedazuridine | 22 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 22 | 12 |
| Posaconazole | Posaconazole | 20 | suppressed |
| Tasigna | Nilotinib Hcl | 20 | suppressed |
| Alunbrig | Brigatinib | 17 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Revlimid | Lenalidomide | 16 | suppressed |
| Tibsovo | Ivosidenib | 16 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Alecensa | Alectinib Hcl | 13 | suppressed |
| Sprycel | Dasatinib | 13 | suppressed |
| Varubi | Rolapitant Hcl | 13 | suppressed |
| Xpovio | Selinexor | 13 | suppressed |
| Ibrance | Palbociclib | 12 | suppressed |
| Scemblix | Asciminib Hydrochloride | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,889.68 · 49 records | Merck Sharp & Dohme LLC | ALIYA SYSTEM, AYVAKIT, BLENREP, CABLIVI, CABOMETYX, CARVYKTI, DATROWAY, ENHERTU, EPKINLY, IMBRUVICA, IMFINZI, INJECTAFER, KEYTRUDA, KEYTRUDA QLEX, MONOFERRIC, OPDIVO, OPDUALAG, RYBREVANT, RYTELO, SCEMBLIX, Tecentriq, XPOVIO, Yescarta, ZEPZELCA | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ayvakit play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error